LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) has appointed seasoned executive Dr Eleanor Kolossovski as director of product marketing as the firm gears up for the commercial manufacturing and launch of its LX Analyzer.
Last month, the firm revealed it was accelerating the submission of its LX Analyzer to the US Food and Drug Administration (FDA) as the coronavirus (COVID-19) outbreak worsens.
Kolossovski will help lead the development of LexaGene’s go-to-market strategy for the LX Analyzer, as well as build brand awareness to propel significant growth opportunities in clinical diagnostics, veterinary diagnostics, food safety testing, and other applied market segments, the biotech firm said in a statement.
She has held multiple sales and marketing positions with companies in the clinical diagnostics space such as BD (Becton, Dickinson and Company), Roche, and Qiagen.
Most recently, she was senior global product manager at Qiagen, where she led the worldwide launch of kits for genetic analysis and a portable qPCR cycler with a particular focus on the public health and applied testing market segments.
"LexaGene is at an exciting phase of our growth trajectory," said Dr Jack Regan, CEO and co-founder of LexaGene. "I’m delighted to have Eleanor join the leadership team to help us successfully launch our automated, on-site genetic analyzer to help with the ever-desperate need for rapid gold standard diagnostics.”
Daryl Rebeck, LexaGene’s President and co-founder, added: "Multiplexed diagnostics like LexaGene’s analyzer, where healthcare providers can test for multiple pathogens and get answers on what is causing symptoms, are particularly useful for COVID-19 testing.
"On the other hand, singleplex rapid tests that are only looking for one virus can frustrate healthcare providers who may question whether the test returned a false negative result or if the patient is sick with something they hadn’t tested for such as the flu."
Contact the author at [email protected]